phosphorylcholine has been researched along with Cancer of Pancreas in 14 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phosphorylcholine (PC) has been used to improve the water solubility and biocompatibility of biomaterials." | 1.62 | Phosphorylcholine-Installed Nanocarriers Target Pancreatic Cancer Cells through the Phospholipid Transfer Protein. ( Anraku, Y; Cabral, H; Hong, T; Koji, K; Matsumoto, A; Miyahara, Y; Miyazaki, T, 2021) |
| "Both breast and pancreatic cancer cells showed higher PE compared with their nonmalignant counterparts." | 1.48 | Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells. ( Bhujwalla, ZM; Glunde, K; Krishnamachary, B; Shah, T; Wijnen, JP; Wildes, F, 2018) |
| "The pancreatic cancer has extremely low overall 5-year survival, and gemcitabine is the only approved single agent for pancreatic cancer treatment." | 1.40 | Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency. ( Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y, 2014) |
| "Perifosine treatment suppressed the phosphorylation of Akt downstream targets such as GSK3α/β, MDM2, and p70S6K and induced apoptosis." | 1.38 | Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. ( Auernhammer, CJ; Brand, S; Göke, B; Lahm, H; Spöttl, G; Vlotides, G; Zitzmann, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Wada, Y | 1 |
| Okano, K | 1 |
| Sato, K | 1 |
| Sugimoto, M | 1 |
| Shimomura, A | 1 |
| Nagao, M | 1 |
| Matsukawa, H | 1 |
| Ando, Y | 1 |
| Suto, H | 1 |
| Oshima, M | 1 |
| Kondo, A | 1 |
| Asano, E | 1 |
| Kishino, T | 1 |
| Kumamoto, K | 1 |
| Kobara, H | 1 |
| Kamada, H | 1 |
| Masaki, T | 1 |
| Soga, T | 1 |
| Suzuki, Y | 2 |
| Hong, T | 1 |
| Miyazaki, T | 1 |
| Matsumoto, A | 1 |
| Koji, K | 1 |
| Miyahara, Y | 1 |
| Anraku, Y | 1 |
| Cabral, H | 1 |
| Shah, T | 1 |
| Krishnamachary, B | 1 |
| Wildes, F | 1 |
| Wijnen, JP | 1 |
| Glunde, K | 1 |
| Bhujwalla, ZM | 1 |
| Xin, Y | 1 |
| Shen, XD | 1 |
| Cheng, L | 1 |
| Hong, DF | 1 |
| Chen, B | 1 |
| Yamada, H | 1 |
| Hasegawa, Y | 1 |
| Imai, H | 1 |
| Matsuda, T | 1 |
| Kimura, Y | 1 |
| Toshimitsu, A | 1 |
| Aoyama, Y | 1 |
| Kondo, T | 1 |
| Chen, Y | 1 |
| Li, Z | 1 |
| Wang, H | 1 |
| Wang, Y | 1 |
| Han, H | 1 |
| Jin, Q | 1 |
| Ji, J | 1 |
| Park, MK | 1 |
| Lee, HJ | 1 |
| Shin, J | 1 |
| Noh, M | 1 |
| Kim, SY | 1 |
| Lee, CH | 1 |
| Busch, T | 1 |
| Armacki, M | 1 |
| Eiseler, T | 1 |
| Joodi, G | 1 |
| Temme, C | 1 |
| Jansen, J | 1 |
| von Wichert, G | 2 |
| Omary, MB | 2 |
| Spatz, J | 3 |
| Seufferlein, T | 3 |
| Zitzmann, K | 1 |
| Vlotides, G | 1 |
| Brand, S | 1 |
| Lahm, H | 1 |
| Spöttl, G | 1 |
| Göke, B | 1 |
| Auernhammer, CJ | 1 |
| Beil, M | 2 |
| Micoulet, A | 2 |
| Paschke, S | 1 |
| Walther, P | 1 |
| Van Veldhoven, PP | 1 |
| Gern, U | 1 |
| Wolff-Hieber, E | 1 |
| Eggermann, J | 1 |
| Waltenberger, J | 1 |
| Adler, G | 1 |
| Maruyama, S | 1 |
| Hu, J | 1 |
| Yamanaka, A | 1 |
| Ichimura, T | 1 |
| Suresh, S | 1 |
| Mills, JP | 1 |
| Dao, M | 1 |
| Lim, CT | 1 |
| Marsh, Rde W | 1 |
| Rocha Lima, CM | 1 |
| Levy, DE | 1 |
| Mitchell, EP | 1 |
| Rowland, KM | 1 |
| Benson, AB | 1 |
| Yamada, T | 1 |
| Okajima, F | 1 |
| Ohwada, S | 1 |
| Kondo, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma[NCT00059982] | Phase 2 | 0 participants | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phosphorylcholine and Cancer of Pancreas
| Article | Year |
|---|---|
Connections between single-cell biomechanics and human disease states: gastrointestinal cancer and malaria.
Topics: Animals; Biomechanical Phenomena; Cell Line, Tumor; Elasticity; Erythrocyte Deformability; Erythrocy | 2005 |
1 trial available for phosphorylcholine and Cancer of Pancreas
| Article | Year |
|---|---|
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antiemetics; Child; Disease Progression; Drug Administra | 2007 |
12 other studies available for phosphorylcholine and Cancer of Pancreas
| Article | Year |
|---|---|
Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer.
Topics: Antigens, CD; Carcinoma, Pancreatic Ductal; Carnitine; Chemoradiotherapy; Glutathione; Humans; Neoad | 2022 |
Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer.
Topics: Antigens, CD; Carcinoma, Pancreatic Ductal; Carnitine; Chemoradiotherapy; Glutathione; Humans; Neoad | 2022 |
Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer.
Topics: Antigens, CD; Carcinoma, Pancreatic Ductal; Carnitine; Chemoradiotherapy; Glutathione; Humans; Neoad | 2022 |
Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer.
Topics: Antigens, CD; Carcinoma, Pancreatic Ductal; Carnitine; Chemoradiotherapy; Glutathione; Humans; Neoad | 2022 |
Phosphorylcholine-Installed Nanocarriers Target Pancreatic Cancer Cells through the Phospholipid Transfer Protein.
Topics: Humans; Micelles; Pancreatic Neoplasms; Phospholipid Transfer Proteins; Phosphorylcholine; Polyethyl | 2021 |
Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Epithelial Cells; Ethan | 2018 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Pr | 2014 |
Magnetic resonance imaging of tumor with a self-traceable polymer conjugated with an antibody fragment.
Topics: Animals; Carbon Isotopes; Cell Line, Tumor; Female; Humans; Immunoconjugates; Magnetic Resonance Ima | 2015 |
IR-780 Loaded Phospholipid Mimicking Homopolymeric Micelles for Near-IR Imaging and Photothermal Therapy of Pancreatic Cancer.
Topics: Animals; Cell Line, Tumor; Contrast Media; Heterografts; Humans; Hyperthermia, Induced; Indoles; Mal | 2016 |
Novel participation of transglutaminase-2 through c-Jun N-terminal kinase activation in sphingosylphosphorylcholine-induced keratin reorganization of PANC-1 cells.
Topics: Anthracenes; Cell Line, Tumor; Cell Movement; Cystamine; Cytoskeleton; Gene Expression Regulation, N | 2011 |
Keratin 8 phosphorylation regulates keratin reorganization and migration of epithelial tumor cells.
Topics: Cell Line, Tumor; Cell Movement; Cytoskeleton; Epithelial Cells; Extracellular Signal-Regulated MAP | 2012 |
Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Topics: Apoptosis; Bronchial Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Huma | 2012 |
Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells.
Topics: Actin Cytoskeleton; Carcinoma; Cell Movement; Cell Size; Cytoskeleton; Elasticity; Fluorescent Antib | 2003 |
A synthetic polymer, poly(2-methacryloyloxyethyl phosphorylcholine-co-n-stearyl methacrylate), stimulates insulin release from RINm5F insulinoma cells.
Topics: Animals; Cell Proliferation; Exocytosis; Insulin; Insulin Secretion; Insulinoma; Methacrylates; Panc | 2004 |
Growth inhibition of human pancreatic cancer cells by sphingosylphosphorylcholine and influence of culture conditions.
Topics: 3T3 Cells; Animals; Cattle; Cell Culture Techniques; Cell Cycle; Cell Division; Ceramides; DNA; Huma | 1997 |